
RenovoRx (RNXT) Stock Forecast & Price Target
RenovoRx (RNXT) Analyst Ratings
Bulls say
RenovoRx is well positioned for long term growth due to the strong commercialization of their FDA-cleared RenovoCath medical device and continued progress in their clinical trials. The company is expected to have significant revenue growth in 2026 and 2027, and its current valuation is attractive considering the potential market opportunities. Risks to the company include its balance sheet and liquidity risks, as well as uncertainties related to product development and regulatory approvals. However, the potential market for RenovoRx's therapies presents high rewards for investors.
Bears say
RenovoRx is facing significant challenges as it continues to develop its TAMP platform and drug candidate RenovoGem. Despite positive interim analysis results in 2023 and 2025, the overall market potential for pancreatic cancer treatment remains low, and the commercialization of RenovoCath may not be enough to support the company's financial growth in the near future. Investor confidence may also be affected by the limited success of previous TAMP therapies and the highly competitive landscape of the biopharmaceutical industry.
This aggregate rating is based on analysts' research of RenovoRx and is not a guaranteed prediction by Public.com or investment advice.
RenovoRx (RNXT) Analyst Forecast & Price Prediction
Start investing in RenovoRx (RNXT)
Order type
Buy in
Order amount
Est. shares
0 shares